Rationale for supporting stepwise access to safe plasma proteins through local production in low- and middle-income countries: A commentary of an international workshop

Shortage of plasma-derived products: a looming crisis?

(2022) Mischa Li Covington et al.   BLOOD

Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia

(2022) Manuel Carcao et al.   HAEMOPHILIA

Emicizumab state‐of‐the‐art update

(2022) Johnny Mahlangu et al.   HAEMOPHILIA

Stepwise access to safe plasma proteins in resource‐constrained countries: Local production and pathways to fractionation—Report of an International Society of Blood Transfusion Workshop

(2022) Thierry Burnouf et al.   VOX SANGUINIS

Low‐dose prophylaxis and its impact on the health of haemophilia patients

(2022) Shrimati Shetty et al.   VOX SANGUINIS

Plasma procurement and plasma product safety in light of the COVID ‐19 pandemic from the perspective of the plasma industry

(2022) Peter L. Turecek et al.   VOX SANGUINIS

Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence

(2021) Kanjaksha Ghosh et al.   Expert Review of Hematology

The case for equitable haemophilia care

(2021) Alok Srivastava   Lancet Haematology

Eptacog Beta for Bleeding Treatment and Prevention in Congenital Hemophilia A and B With Inhibitors: A Review of Clinical Data and Implications for Clinical Practice

(2021) Alana M. Ciolek et al.   ANNALS OF PHARMACOTHERAPY

The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality

(2020) E. Carlos Rodriguez-Merchan   Expert Review of Hematology

The World Federation of Hemophilia Annual Global Survey 1999‐2018

(2020) Jeffrey S. Stonebraker et al.   HAEMOPHILIA

WFH Guidelines for the Management of Hemophilia, 3rd edition

(2020) Alok Srivastava et al.   HAEMOPHILIA

Global immunoglobulin supply: steaming towards the iceberg?

(2020) Johan Prevot et al.   Current Opinion in Allergy and Clinical Immunology

Supply and demand for plasma‐derived medicinal products – a critical re‐assessment amidst the COVID ‐19 pandemic

(2020) Jan Hartmann et al.   TRANSFUSION

Model‐based evaluation of low‐dose factor VIII prophylaxis in haemophilia A

(2019) Ari Brekkan et al.   HAEMOPHILIA

Low Dose Prophylaxis in Hemophilia Care

(2019) Neeraj Sidharthan et al.   INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION

Improving haemophilia therapy in developing countries: virus‐safe cryoprecipitate

(2019) Jean‐Claude Faber et al.   VOX SANGUINIS

Selection of Blood, Blood Components, and Blood Products as Essential Medicines in 105 Low- and Middle-Income Countries

(2019) Washington T. Samukange et al.   TRANSFUSION MEDICINE REVIEWS

Plasma fractionation in countries with limited infrastructure and low-/medium income: How to move forward?

(2019) Thierry Burnouf et al.   TRANSFUSION AND APHERESIS SCIENCE

Bitter progress in the treatment of haemophilia A in low-income countries

(2018) Jean-Claude Faber et al.   Lancet Haematology

Plasma is a strategic resource

(2016) Paul F.W. Strengers et al.   TRANSFUSION

A multicomponent strategy to improve the availability of antivenom for treating snakebite envenoming

(2014) José María Gutiérrez et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Plasma fractionation issues

(2009) Albert Farrugia et al.   BIOLOGICALS